PR

Wallstreetcn · Jan 14 at 07:50 PM

AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

Wallstreetcn · Jan 14 at 05:57 AM

PR: At this stage, the direct revenue from the company's DiOrion platform drug development services accounts for a small proportion of the company's overall operating income, which does not have a significant impact on the company's overall operating situation

Zhitong · Oct 29, 2025 at 04:54 AM

PR released its performance for the first three quarters, with a net profit attributable to the parent company of 34.7496 million yuan, an increase of 127.96%

Zhitong · Oct 29, 2025 at 02:58 AM

PR: It plans to distribute 13.754 million yuan in cash for the first three quarters of 2025

Zhitong · Oct 29, 2025 at 12:15 AM

The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

Zhitong · Sep 24, 2025 at 08:19 PM

PR: The company's business includes the weight loss sector